This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Starting
Monitoring
Lab Abnormalities
CIBINQO is not recommended for patients with severe renal or hepatic impairment.
Advise patients who can become pregnant that CIBINQO may impair fertility† and to report pregnancies that occur during treatment to the pregnancy exposure registry by calling 1-877-311-3770 or visiting CIBINQOPregnancyRegistry.com. Patients should not breastfeed during treatment with CIBINQO and for 1 day after the last dose.
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO.
Explore resources for you and your patients
Laboratory evaluations may be extended for patients who develop hematologic abnormalities.
*Prescribing Information recommendation for lipid parameters: at 4 weeks after initiation and thereafter according to hyperlipidemia guidelines.
Explore resources for you and your patients
Explore resources for you and your patients
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.